Characteristics of Dapagliflozin Responders: A Longitudinal, Prospective, Nationwide Dapagliflozin Surveillance Study in Korea

Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders
Eugene HanByung-Wan Lee

Abstract

Sodium glucose co-transporter 2 (SGLT2) inhibitors, such as dapagliflozin, have demonstrated favorable effects in patients with type 2 diabetes (T2D). However, there are limited reports in the literature regarding the glucose-lowering effects of SGLT2 inhibitors in actual clinical settings. The post-marketing surveillance data from a longitudinal prospective study of 2007 patients with T2D who were prescribed dapagliflozin (10 mg/day) were analyzed (ClinicalTrials.gov, NCT02252224). After 12 weeks of dapagliflozin treatment, glycated hemoglobin (HbA1c) and body mass index were significantly decreased (P < 0.001) from 8.1 ± 1.3% to 7.5 ± 1.2% and from 28.1 ± 4.4 to 27.6 ± 4.2 kg/m2, respectively. Both body weight and HbA1c were reduced in 67.7% of patients, and HbA1c was lowered in 75.1%. Younger age, male sex, shorter diabetes duration, higher baseline HbA1c and estimated glomerular filtration rate (eGFR), and having dapagliflozin as add-on therapy were associated with stronger HbA1c reductions after dapagliflozin use (all P < 0.05). Moreover, subgroup analysis of eGFR of subjects with renal hyperfiltration (eGFR ≥ 120 ml/min/1.73 m2) showed the largest reduction in glucose level (% change, - 9.5; 95% CI - 6.8 to - 12.3 for HbA...Continue Reading

References

Mar 3, 2007·Kidney International·M TomaszewskiA F Dominiczak
May 6, 2009·Annals of Internal Medicine·Andrew S LeveyUNKNOWN CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration)
May 25, 2011·Endocrine Reviews·Muhammad A Abdul-GhaniRalph A Defronzo
Feb 22, 2012·Nature Reviews. Nephrology·Imed HelalRobert W Schrier
Jan 28, 2014·The Journal of Clinical Investigation·Ele FerranniniHans-Juergen Woerle
Mar 15, 2014·Diabetes & Metabolism Journal·Chul Sik KimUNKNOWN Taskforce Team of Diabetes Fact Sheet of the Korean Diabetes Association
Sep 13, 2014·Diabetes & Metabolism Journal·Chang Hee JungJoong-Yeol Park
Jan 21, 2015·Diabetes, Obesity & Metabolism·M J DaviesG Meininger
Sep 18, 2015·The New England Journal of Medicine·Bernard ZinmanUNKNOWN EMPA-REG OUTCOME Investigators
Oct 20, 2015·Expert Opinion on Pharmacotherapy·Yuta NakamuraYasushi Tanaka
Dec 1, 2015·Diabetes & Metabolism Journal·Eun Hee SimYang Ho Kang
Mar 18, 2017·Clinical Journal of the American Society of Nephrology : CJASN·Sergei PetrykivHiddo J L Heerspink
Nov 25, 2017·Diabetes, Obesity & Metabolism·Motoshi OuchiNaohiko Anzai

❮ Previous
Next ❯

Citations

Nov 23, 2018·Expert Opinion on Drug Metabolism & Toxicology·Alvaro Garcia-RoperoCarlos G Santos-Gallego
Jun 27, 2019·Drugs·Sohita Dhillon
Jul 30, 2021·Current Opinion in Pharmacology·Ilaria CampesiFlavia Franconi

❮ Previous
Next ❯

Clinical Trials Mentioned

NCT02252224

Software Mentioned

NCSS
SAS

Related Concepts

Related Feeds

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.